Skip to main content

MaxCyte, Inc.

corporate_fare Company Profile

MaxCyte, Inc.

MXCT·NASDAQ·Industrial Applications And Services·CIK 0001287098

We are a leading commercial cell engineering company providing platform technologies for the discovery, development, and commercialization of next-generation cell therapeutics, including cell and gene therapies, and for innovative cell-based research and development. For over two decades, we have developed and commercialized our proprietary Flow Electroporation® technology. This technology is used by biopharmaceutical companies for the complex engineering of various cells. Electroporation is a method of transfection, which is the process of deliberately introducing molecules into cells by applying an electric field to temporarily increase the cell membrane's permeability. This controlled increase in permeability allows for the intracellular delivery of molecules, such as genetic material and proteins, that would not normally cross the cell membrane easily. Researchers leverage cell functions and machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has advanced biological research and led to numerous discoveries. Living human cells can also be engineered ex vivo, or outside the body, where they are repaired or reprogrammed to fight disease, with the engineered cell itself acting as the drug. Cell therapy is a rapidly growing treatment modality for human diseases. Recent developments in multiple U.S. Food and Drug Administration (FDA) approved cell therapies show promising data, suggesting they may provide long-lasting symptom amelioration or disease presence, which has driven significant investment and growth in cell-based therapies for therapeutic applications.

MaxCyte, Inc. (NASDAQ:MXCT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for MXCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for MXCT spans 10-Q, 8-K, SCHEDULE 13D, 10-K.

Recent high-impact activity:

  • MaxCyte 10-Q: Q3 Revenue Up 49% to $10.2M, Net Loss Narrows to $4.8M Ahead of $151.8M Akron Deal
  • MaxCyte Sinks 10% as $151.8M Akron Bio Buyout Dilutes Shareholders
  • MaxCyte to Pay $151.8M for Akron Bio: $105M Cash, 20.6M Shares, $20M Deferred
  • Q3 Revenue Jumps 49% to $10.2M, Full-Year Guidance Raised to at Least $34.5M
  • MaxCyte to Buy Akron Bio, Expects Deal to Nearly Double Revenue Base

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$33.03M
Net Income
-$44.63M
Diluted EPS
-$0.42
Op. Cash Flow
-$34.41M
Free Cash Flow
-$36.18M
Gross Profit
$26.8M
Operating Income
-$51.9M
Cash & Equivalents
$20.07M
Debt / Equity
0.00×
Net Margin
-135.1%
Shares Outstanding
106.79M sh
Source: 10-K · filed 2026-03-25 · accession 0001104659-26-034557

Short Interest & Short Volume

1.34 days to cover

FINRA reported short interest of 1,583,224 shares in MXCT as of the October 30, 2026 settlement, a 13.6% decrease from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 11.1% of MXCT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,583,224 shares as of October 30, 2026
Change vs prior period▼ 13.6%
Days to cover1.34 at avg daily volume of 1,177,944
Daily short volume (FINRA facilities)11.1% of 483,330 shares on November 20, 2026
5-day average short volume16.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$1.37
52-week range · as of 2026-11-10 $0.6434 – $1.8
Market cap
$141.45M
Volume
1.1M (0.6× avg)
3-mo avg 1.8M
Live data · 2026-11-21 14:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MXCT - Latest Insights

MXCT
Nov 10, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.37 info
Change: +$0.180 (+15%) info
Market Cap: $141.453M info
MXCT
Nov 10, 2026, 12:40 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.37 info
Change: +$0.215 (+19%) info
Market Cap: $141.453M info
MXCT
Nov 10, 2026, 8:21 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.36
Real-time Price: $1.37 info
Change: +$0.010 (+0.74%) info
Market Cap: $141.453M info
MXCT
Nov 10, 2026, 6:01 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.37 info
Change: -$0.060 (-4%) info
Market Cap: $141.453M info
MXCT
Nov 10, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.37 info
Change: +$0.1396 (+11%) info
Market Cap: $141.453M info
MXCT
Oct 14, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.00
Real-time Price: $1.37 info
Change: +$0.370 (+37%) info
Market Cap: $141.453M info
MXCT
Aug 04, 2026, 8:42 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $1.37 info
Change: +$0.310 (+29%) info
Market Cap: $141.453M info
MXCT
Jul 21, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $1.37 info
Change: +$0.1556 (+13%) info
Market Cap: $141.453M info
MXCT
Jun 16, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $1.37 info
Change: +$0.230 (+20%) info
Market Cap: $141.453M info
MXCT
Jun 16, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $1.37 info
Change: +$0.230 (+20%) info
Market Cap: $141.453M info
MXCT
May 14, 2026, 9:44 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $1.37 info
Change: +$0.320 (+30%) info
Market Cap: $141.453M info
MXCT
May 13, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $1.37 info
Change: +$0.340 (+33%) info
Market Cap: $141.453M info
MXCT
May 12, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9003
Real-time Price: $1.37 info
Change: +$0.4697 (+52%) info
Market Cap: $141.453M info
MXCT
Mar 27, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6745
Real-time Price: $1.37 info
Change: +$0.6955 (+103%) info
Market Cap: $141.453M info
MXCT
Mar 25, 2026, 4:36 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.688
Real-time Price: $1.37 info
Change: +$0.682 (+99%) info
Market Cap: $141.453M info
MXCT
Mar 24, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.701
Real-time Price: $1.37 info
Change: +$0.669 (+95%) info
Market Cap: $141.453M info
MXCT
Mar 20, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7421
Real-time Price: $1.37 info
Change: +$0.6279 (+85%) info
Market Cap: $141.453M info
MXCT
Jan 12, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $1.37 info
Change: +$0.010 (+0.74%) info
Market Cap: $141.453M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets